Alkermes (ALKS) is down -10.7%, or -$3.61 to $30.20.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALKS:
- Alkermes Phase 2 narcolepsy study details ‘scant,’ says Truist
- Alkermes Announces Positive Results from Vibrance-2 Study
- Alkermes down 14% at $29.00 after Vibrance-2 Phase 2 alixorexton study data
- Alkermes’ Alixorexton Shows Promising Results in NT2 Patients, Justifying Buy Rating
- Alkermes says ‘positive’ results from Vibrance-2 Phase 2 study of alixorexton